Targeted therapies left out of ASCO breast cancer guideline for now
This article was originally published in Scrip
The American Society of Clinical Oncology (ASCO) released a new treatment guideline on 2 September for women with HER2-negative advanced or metastatic breast cancer that appears to be in line with how doctors already treat patients with later-stage disease and excludes the few available targeted therapies.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.